Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 46

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth

Hoy, James J., Salinas Parra, Natalia, Park, Jeannie, Kuhn, Skyler, Iglesias‐Bartolome, Ramiro · 2020 · The FASEB Journal

Abstract

The PKA‐inhibitor (PKI) family members PKIα, PKIβ, and PKIγ bind with high affinity to PKA and block its kinase activity, modulating the extent, and duration of PKA‐mediated signaling events. While PKA is a well‐known regulator of physiological and oncogenic events, the role of PKI proteins in these pathways has remained elusive. Here, by measuring activation of the MAPK pathway downstream of GPCR‐Gαs‐cAMP signaling, we show that the expression levels of PKI proteins can alter the balance of activation of two major cAMP targets: PKA and EPAC. Our results indicate that PKA maintains repressive control over MAPK signaling as well as a negative feedback on cAMP concentration. Overexpression of PKI and its subsequent repression of PKA dysregulates these signaling pathways, resulting in increased intracellular cAMP, and enhanced activation of EPAC and MAPK. We also find that amplifications of PKIA are common in prostate cancer and are associated with reduced progression free survival. Depletion of PKIA in prostate cancer cells leads to reduced migration, increased sensitivity to anoikis and reduced tumor growth. By altering PKA activity PKI can act as a molecular switch, driving GPCR‐Gαs‐cAMP signaling toward activation of EPAC‐RAP1 and MAPK, ultimately modulating tumor growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.202001515r

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 61

  1. 10.1038/nrc3521 · DOI · Paper page
  2. 10.1056/NEJM199112123252403 · DOI · Paper page
  3. 10.1038/340692a0 · DOI · Paper page
  4. 10.1038/ncb3164 · DOI · Paper page
  5. 10.1038/nm.3666 · DOI
  6. 10.1016/j.ccr.2014.02.004 · DOI · Paper page
  7. 10.1111/j.1745-7270.2008.00438.x · DOI · Paper page
  8. 10.1016/S0962-8924(02)02294-8 · DOI · Paper page
  9. 10.1002/jcp.21246 · DOI · Paper page
  10. 10.1038/sj.onc.1210407 · DOI · Paper page
  11. 10.1124/pr.110.003707 · DOI · Paper page
  12. Jewell JL, 2019, GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor, eLife, 8, 1, 10.7554/eLife.43038 · DOI
  13. 10.1038/emboj.2013.102 · DOI · Paper page
  14. 10.1101/gad.219402.113 · DOI · Paper page
  15. Ashby CD, 1972, Characterization of the interaction of a protein inhibitor with adenosine 3',5'‐monophosphate‐dependent protein kinases. I. Interaction with the catalytic subunit of the protein kinase, J Biol Chem, 247, 6637, 10.1016/S0021-9258(19)44739-X · DOI · Paper page
  16. Ashby CD, 1973, Characterization of the interaction of a protein inhibitor with adenosine 3′,5′‐monophosphate‐dependent protein kinases. II. Mechanism of action with the holoenzyme, J Biol Chem, 248, 1255, 10.1016/S0021-9258(19)44290-7 · DOI · Paper page
  17. 10.1016/j.npep.2005.10.002 · DOI · Paper page
  18. 10.1146/annurev.bi.59.070190.004543 · DOI · Paper page
  19. 10.1016/S0021-9258(18)31623-5 · DOI
  20. 10.1016/0092-8674(95)90435-2 · DOI · Paper page
  21. 10.1128/MCB.20.10.3442-3448.2000 · DOI · Paper page
  22. 10.1128/MCB.21.12.3959-3963.2001 · DOI · Paper page
  23. 10.1161/CIRCRESAHA.112.273896 · DOI
  24. 10.1074/jbc.M113.466904 · DOI
  25. 10.1016/j.molcel.2012.10.018 · DOI · Paper page
  26. 10.1126/scitranslmed.aap8798 · DOI · Paper page
  27. 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
  28. 10.1126/scisignal.2004088 · DOI · Paper page
  29. 10.1038/24884 · DOI · Paper page
  30. 10.1146/annurev.pharmtox.010909.105714 · DOI · Paper page
  31. Bos JL, 2018, From Ras to Rap and back, a journey of 35 years, Cold Spring Harb Perspect Med, 8, 1
  32. 10.1074/jbc.273.23.14533 · DOI
  33. 10.1074/jbc.M403604200 · DOI
  34. 10.1128/MCB.26.6.2130-2145.2006 · DOI · Paper page
  35. 10.1101/lm.830008 · DOI
  36. 10.1073/pnas.1210209109 · DOI
  37. 10.1038/srep09344 · DOI
  38. 10.1016/S0092-8674(00)80184-1 · DOI · Paper page
  39. 10.1074/jbc.M003327200 · DOI
  40. 10.1177/1947601911407323 · DOI · Paper page
  41. 10.1074/jbc.M116.768986 · DOI
  42. 10.1093/emboj/16.21.6426 · DOI · Paper page
  43. 10.1002/jcp.21354 · DOI
  44. 10.1128/MCB.22.17.6023-6033.2002 · DOI · Paper page
  45. 10.1073/pnas.0813263106 · DOI
  46. 10.1074/jbc.M201491200 · DOI
  47. 10.1074/jbc.270.21.12481 · DOI · Paper page
  48. 10.1016/j.molcel.2006.07.025 · DOI · Paper page
  49. 10.1161/01.RES.0000256354.95791.f1 · DOI · Paper page
  50. 10.1007/978-1-61779-160-4_14 · doi:10.1007/978-1-61779-160-4_14
  51. 10.1021/cb8000414 · DOI · Paper page
  52. 10.1038/nrc2809 · DOI · Paper page
  53. 10.2174/1875397301004010084 · DOI · Paper page
  54. 10.1242/jcs.072165 · DOI · Paper page
  55. 10.1074/jbc.C300182200 · DOI · Paper page
  56. 10.1016/j.celrep.2015.01.046 · DOI · Paper page
  57. 10.1038/s41418-020-0522-3 · DOI · Paper page
  58. 10.1002/(SICI)1097-4547(19980801)53:3<269::AID-JNR1>3.0.CO;2-8 · DOI · Paper page
  59. 10.1038/onc.2009.144 · DOI · Paper page
  60. Manschwetus JT, 2019, A Stapled peptide mimic of the pseudosubstrate inhibitor PKI inhibits protein kinase A, Molecules, 24, 1, 10.3390/molecules24081567 · DOI · Paper page
  61. 10.1016/j.celrep.2016.02.077 · DOI

Cited by

See all 46

Metadata

Authors
Hoy, J. J., Salinas Parra, N., Park, J., Kuhn, S., & Iglesias‐Bartolome, R.
Affiliations
  • Laboratory of Cellular and Molecular Biology Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD USA
  • Collaborative Bioinformatics Resource Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD USA
Venue
The FASEB Journal
Publisher
Wiley
Published
2020-08-24
Volume
34
Issue
10
Pages
13900-13917
ISSN
  • 0892-6638
  • 1530-6860
Cited by
46
References
4
Language
en
Funders
National Cancer Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth. https://app.cochat.ai/papers/10.1096/fj.202001515r
The paper
Hoy, J. J., Salinas Parra, N., Park, J., Kuhn, S., & Iglesias‐Bartolome, R. (2020). Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth. The FASEB Journal. https://doi.org/10.1096/fj.202001515r

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.